Clinical Trial Update: A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (DURGA-4) evaluating AZD0120, a dual-targeted CAR-T therapy against BCMA and CD19, versus standard regimens in relapsed refractory mult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AZD0120

Snippet

Sponsor: AstraZeneca | Conditions: Relapsed Refractory Multiple Myeloma | Phase 3 | Status: RECRUITING